Loading organizations...
Key people at Foxkiser.
Foxkiser was founded in 1983 by Allan M. Fox (Founder & Partner).
FoxKiser LLP operates as a specialized legal services firm, focusing intensely on pharmaceutical and biotechnology litigation. The firm offers comprehensive advisory, partnership, and development services, leveraging deep expertise at the intricate intersection of science, law, and medicine. This targeted approach allows FoxKiser to address the unique and evolving legal challenges faced by innovators within the life sciences industry, providing tailored solutions for their complex needs.
Established over four decades ago, FoxKiser was founded on the insight that the burgeoning fields of biotechnology and pharmaceuticals would require highly specialized legal counsel. The firm’s origin stemmed from a recognition of the critical necessity for legal professionals who not only understood legal frameworks but also possessed a profound grasp of scientific and medical complexities. This foundational premise enabled the firm to build a practice dedicated to this highly technical domain.
The firm primarily serves a clientele comprising pharmaceutical and biotechnology companies navigating intricate regulatory landscapes and litigation matters. FoxKiser's long-term vision centers on continuously delivering innovative legal solutions that bridge scientific discovery with legal compliance and protection. They aim to remain a vital partner for companies driving medical and scientific advancements, ensuring their innovations are legally sound and protected for future development.
Key people at Foxkiser.
Foxkiser was founded in 1983 by Allan M. Fox (Founder & Partner).
Foxkiser has 3 tracked investments across 3 companies. The latest tracked deal is $7.0M Series A in Mightier in May 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2019 | Mightier | $7.0M Series A | Foxkiser | Asymmetric Capital Partners, Founder Collective, Louis Beryl, Tyler Willis, Asset Management Ventures, FundRx, Project 11, Slow Ventures |
| Jun 1, 2018 | WindMIL Therapeutics | $33.0M Series B | Qiming Venture Partners USA | Camden Partners, Domain Associates, Medivate Partners |
| Jan 1, 2015 | REGENXBIO | $30.0M Series C | Venrock, Brookside Capital | ARCH Venture Partners, Deerfield Management, F Prime Capital |